Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

MLA

Randi Ryan, et al. “Feasibility and Advantage of Adding 131I-MIBG to 90Y-DOTATOC for Treatment of Patients with Advanced Stage Neuroendocrine Tumors.” EJNMMI Research, vol. 4, Sept. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1c32725121c136ccb8051652ba4d063b&authtype=sso&custid=ns315887.

APA

Randi Ryan, M. Sue O’Dorisio, David L. Bushnell, Yusuf Menda, Saima Muzahir, Mark T. Madsen, & Thomas O’cdorisio. (2014). Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Research, 4.

Chicago

Randi Ryan, M. Sue O’Dorisio, David L. Bushnell, Yusuf Menda, Saima Muzahir, Mark T. Madsen, and Thomas O’cdorisio. 2014. “Feasibility and Advantage of Adding 131I-MIBG to 90Y-DOTATOC for Treatment of Patients with Advanced Stage Neuroendocrine Tumors.” EJNMMI Research 4 (September). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1c32725121c136ccb8051652ba4d063b&authtype=sso&custid=ns315887.